RankAlpha logo

XERS

AI Memo

Xeris Biopharma

As of 2026-09-24/Confidence medium
Open tickerBack to Memos
Data freshness
AI Memo
As of 2026-09-24 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action
—
Confidence
medium
Horizon
—
Key catalyst
FY2026 revenue-guidance delivery • 2026-12-31
Base target: $10 / p=50% prob
Biggest risk
Recorlev concentration, rising commercial and R&D spending, and a long, uncertain XP-8121 trial-to-approval path could outweigh current sales growth. Q2 Gvoke revenue declined 4% year over year, while the reported net loss included a roughly $31 million noncash convertible-note charge [#SEC-8K-2026-08-06].
Invalidation
Break below $6 or thesis failure.
What would change my mind?
Recorlev's 81% second-quarter growth, improved gross margin and delivery of $385 million–$390 million FY2026 revenue guidance could support a rerating. An on-time XP-8121 Phase 3 start adds a distinct, longer-duration opportunity [#SEC-8K-2026-08-06] [#8-K-2026-09-09].
Research note
Recommendation
—
Confidence
medium
As of
2026-09-24
Base target
$10
p=50%
Bull target
$12
p=25%
Bear target
$6
p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets
  • Recorlev commercial momentum
  • XP-8121 Cornerstone readout
  • Recorlev's 81% second-quarter growth, improved gross margin and delivery of $385 million–$390 million FY2026 revenue guidance could support a rerating.
BearKey bullets
  • FY2026 guidance depends on sustained Recorlev demand and the productivity of commercial investment; Q2 SG&A rose 37% year over year [#SEC-8K-2026-08-06].
  • Keveyis patent protection through at least 2039 remains conditional on the allowed application being granted [#SEC-8K-2026-08-06].
  • The convertible-note exchanges removed the 2028 notes but involved cash and share issuance, creating dilution and capital-allocation considerations [#SEC-8K-2026-08-06].
WatchKey bullets
  • FY2026 revenue-guidance delivery

Summary

High-level snapshot

Recommendation
-
Model confidence
medium
Timeframe
-
Asset
Equity
Trigger
-
Base case: $10 (p=50%)
Target spread vs base: +26% / -42%
Scenario probabilities
Bull Target: $12 (p=25%)Base Target: $10 (p=50%)Bear Target: $6 (p=25%)
Commentary
Company-source tone is constructive on commercial growth and the now-specified XP-8121 program, but the September 9 presentation is a development plan rather than efficacy evidence. Verified recent price-reaction attribution, analyst revisions, options data, short interest and sufficient social coverage are unavailable; the zero sentiment fields denote unavailable inputs, not neutral measurements. Insider Form 4 sales are not evidence of operating performance.
As of 2026-09-24 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case
Recorlev's 81% second-quarter growth, improved gross margin and delivery of $385 million–$390 million FY2026 revenue guidance could support a rerating. An on-time XP-8121 Phase 3 start adds a distinct, longer-duration opportunity [#SEC-8K-2026-08-06] [#8-K-2026-09-09].
Bear Case
Recorlev concentration, rising commercial and R&D spending, and a long, uncertain XP-8121 trial-to-approval path could outweigh current sales growth. Q2 Gvoke revenue declined 4% year over year, while the reported net loss included a roughly $31 million noncash convertible-note charge [#SEC-8K-2026-08-06].

Drivers

Scannable catalysts and supporting factors

  • Recorlev commercial momentum
  • XP-8121 Cornerstone readout

Scenarios

Bull Target (Scenario probability)
$12 / p=25% prob
Base Target (Scenario probability)
$10 / p=50% prob
Bear Target (Scenario probability)
$6 / p=25% prob
Analysis 2026-09-24 · RankAlpha Sentiment Codex
Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)
0.00
Social Sentiment (7d)
0.00

Events

Other notable items detected

  • EVENT2026-12-31
    FY2026 revenue-guidance delivery
    Xeris tightened full-year revenue guidance to $385 million–$390 million after reporting $175.2 million of first-half revenue. The range makes second-half execution measurable; December 31 is the fiscal-period end, not an announced results date [#SEC-8K-2026-08-06]. SEC earnings exhibit
    Prob 68.00% • Move 14.00% • Priced-in 60.00%
  • EVENT2026-12-31
    XP-8121 Phase 3 initiation
    At its September 9 program overview, Xeris said the 500-participant Cornerstone registrational study remained on track to start by year-end 2026. An on-time start would validate the development schedule, not clinical efficacy [#8-K-2026-09-09]. SEC-filed company release
    Prob 70.00% • Move 8.00% • Priced-in 60.00%

Short-term Catalysts

Next few weeks

  • Recorlev commercial momentum
    2026-12-31
    Second-quarter Recorlev revenue rose 81% year over year to $56.8 million, driving 34% net-product-revenue growth. Sustained patient demand and returns on the expanded commercial organization are the near-term test [#SEC-8K-2026-08-06]. SEC earnings exhibit
    Prob 70% • Move 10% • Priced-in 65%

Long-term Catalysts

Months to a year

  • XP-8121 Cornerstone readout
    2028-12-31
    Xeris expects late-2028 topline results from Cornerstone, which will test once-weekly XP-8121 against daily oral levothyroxine on thyroid-stimulating-hormone control. Trial execution, non-inferiority and regulatory acceptance remain material uncertainties; the company's $1 billion–$3 billion peak-revenue estimate is an aspiration, not a forecast used in the price targets [#8-K-2026-09-09]. SEC-filed company release
    Prob 50% • Move 30% • Priced-in 35%

Risks

  • FY2026 guidance depends on sustained Recorlev demand and the productivity of commercial investment; Q2 SG&A rose 37% year over year [#SEC-8K-2026-08-06].
  • Keveyis patent protection through at least 2039 remains conditional on the allowed application being granted [#SEC-8K-2026-08-06].
  • The convertible-note exchanges removed the 2028 notes but involved cash and share issuance, creating dilution and capital-allocation considerations [#SEC-8K-2026-08-06].
  • XP-8121 may start late, enroll slowly, miss non-inferiority, require additional FDA data or fail to gain approval; anticipated 2030 launch and peak-revenue figures are company projections [#8-K-2026-09-09].

Peers

SymbolSummary
ABSISimilar market capitalization and sector classification, but the packet does not establish comparable marketed products or revenue maturity; not a direct valuation anchor.
MAZESimilar-size biopharma candidate, but product, indication and commercial-stage comparability are unverified; use only as a loose risk-context peer.

Sources

Internal and external references used in this analysis

  • Model source: RankAlpha Sentiment Codex
  • Analysis date: 2026-09-24